46 related articles for article (PubMed ID: 27127135)
1. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors.
Abramsson A; Lindblom P; Betsholtz C
J Clin Invest; 2003 Oct; 112(8):1142-51. PubMed ID: 14561699
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis as a therapeutic target in cancer.
Kumaran G; Clamp AR; Jayson GC
Clin Med (Lond); 2008 Aug; 8(4):455-8. PubMed ID: 18724620
[No Abstract] [Full Text] [Related]
3. Vascular endothelial growth factor: a novel potential therapeutic target for hypertension.
Tao H; Shi KH; Yang JJ
J Clin Hypertens (Greenwich); 2013 Jul; 15(7):514. PubMed ID: 23815542
[No Abstract] [Full Text] [Related]
4. Corneal Vascularization Associated With a Novel PDGFRB Variant.
Gladkauskas T; Bruland O; Abu Safieh L; Edward DP; Rødahl E; Bredrup C
Invest Ophthalmol Vis Sci; 2023 Nov; 64(14):9. PubMed ID: 37934158
[TBL] [Abstract][Full Text] [Related]
5. Design, construction and in vivo functional assessment of a hinge truncated sFLT01.
Zakeri F; Latifi-Navid H; Soheili ZS; Sadeghi M; Arab SS; Samiei S; Pirmardan ER; Taghizadeh S; Ahmadieh H; Hafezi-Moghadam A
Gene Ther; 2023 Apr; 30(3-4):347-361. PubMed ID: 36114375
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of Platelet Derived Growth Factor Pathway Gene Expression Profile Defines Three Distinct Subgroups of Renal Cell Carcinomas.
Ferician AM; Ferician OC; Cumpanas AD; Berzava PL; Nesiu A; Barmayoun A; Cimpean AM
Cancer Genomics Proteomics; 2022; 19(4):477-489. PubMed ID: 35732321
[TBL] [Abstract][Full Text] [Related]
7. Cellular crosstalk of glomerular endothelial cells and podocytes in diabetic kidney disease.
Jiang S; Luo M; Bai X; Nie P; Zhu Y; Cai H; Li B; Luo P
J Cell Commun Signal; 2022 Sep; 16(3):313-331. PubMed ID: 35041192
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of platelet-derived growth factor receptor synergistically increases the pharmacological effect of tamoxifen in estrogen receptor α positive breast cancer.
Kim S; You D; Jeong Y; Yoon SY; Kim SA; Lee JE
Oncol Lett; 2021 Apr; 21(4):294. PubMed ID: 33732370
[TBL] [Abstract][Full Text] [Related]
9. Expression of growth factors and their receptors in the primary renal cell carcinoma: new data and review.
Volkova M; Tsimafeyeu I; Olshanskaya A; Khochenkova Y; Solomko E; Ashuba S; Khochenkov D; Matveev V
Cent European J Urol; 2020; 73(4):466-475. PubMed ID: 33552572
[TBL] [Abstract][Full Text] [Related]
10. Growth factors contribute to the mediation of angiogenic capacity of glioma-associated mesenchymal stem cells.
Zhang Q; Xiang W; Xue BZ; Yi DY; Zhao HY; Fu P
Oncol Lett; 2021 Mar; 21(3):215. PubMed ID: 33552293
[TBL] [Abstract][Full Text] [Related]
11. Imatinib‑induced apoptosis of gastric cancer cells is mediated by endoplasmic reticulum stress.
Kim JL; Lee DH; Jeong S; Kim BR; Na YJ; Park SH; Jo MJ; Jeong YA; Oh SC
Oncol Rep; 2019 Mar; 41(3):1616-1626. PubMed ID: 30569109
[TBL] [Abstract][Full Text] [Related]
12. The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study.
Bamias A; Karavasilis V; Gavalas N; Tzannis K; Samantas E; Aravantinos G; Koutras A; Gkerzelis I; Kostouros E; Koutsoukos K; Zagouri F; Fountzilas G; Dimopoulos MA
Int J Clin Oncol; 2019 Apr; 24(4):411-419. PubMed ID: 30374686
[TBL] [Abstract][Full Text] [Related]
13. VEGF-A
Stevens M; Neal CR; Salmon AHJ; Bates DO; Harper SJ; Oltean S
J Physiol; 2017 Oct; 595(19):6281-6298. PubMed ID: 28574576
[TBL] [Abstract][Full Text] [Related]
14. The Involvement of PDGF-B/PDGFRβ Axis in the Resistance to Antiangiogenic and Antivascular Therapy in Renal Cancer.
Cumpănas AA; Cimpean AM; Ferician O; Ceausu RA; Sarb S; Barbos V; Dema A; Raica M
Anticancer Res; 2016 May; 36(5):2291-5. PubMed ID: 27127135
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of vascular endothelial growth factor (VEGF), VEGF receptor 2, platelet-derived growth factor-β (PDGF-β), and PDGF-β receptor expression in papillary renal cell carcinoma.
Kim M; Sohn M; Shim M; Choi SK; Park M; Kim E; Go H; Park Y; Cho YM; Ro JY; Jeong IG; Song C; Hong JH; Kim CS; Ahn H
Hum Pathol; 2017 Mar; 61():78-89. PubMed ID: 27989785
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
Roberts WG; Whalen PM; Soderstrom E; Moraski G; Lyssikatos JP; Wang HF; Cooper B; Baker DA; Savage D; Dalvie D; Atherton JA; Ralston S; Szewc R; Kath JC; Lin J; Soderstrom C; Tkalcevic G; Cohen BD; Pollack V; Barth W; Hungerford W; Ung E
Cancer Res; 2005 Feb; 65(3):957-66. PubMed ID: 15705896
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancer.
Suzuki S; Dobashi Y; Hatakeyama Y; Tajiri R; Fujimura T; Heldin CH; Ooi A
BMC Cancer; 2010 Nov; 10():659. PubMed ID: 21118571
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
Rini BI
Clin Cancer Res; 2007 Feb; 13(4):1098-106. PubMed ID: 17317817
[TBL] [Abstract][Full Text] [Related]
19. Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy.
Saylor PJ; Escudier B; Michaelson MD
Clin Genitourin Cancer; 2012 Jun; 10(2):77-83. PubMed ID: 22382009
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
